Journal of Vascular Surgery
Volume 39, Issue 1 , Pages 20-26 , January 2004

Influence of endograft oversizing on device migration, endoleak, aneurysm shrinkage, and aortic neck dilation: results from the zenith multicenter trial

Presented at the Fifty-seventh Annual Meeting of the Society for Vascular Surgery, Chicago, Ill, June 8-11, 2003.

  • W.Charles Sternbergh III, MD

      Affiliations

    • Corresponding Author InformationReprint requests: W. Charles Sternbergh III, MD, Vascular Surgery Program, Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
    • Ochsner Clinic Foundation, New Orleans, La, USA
    • ,
  • Samuel R Money, MD, MBA

      Affiliations

    • Ochsner Clinic Foundation, New Orleans, La, USA
    • ,
  • Roy K Greenberg, MD

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • ,
  • Timothy A.M Chuter, MD

      Affiliations

    • University of California, San Francisco, San Francisco, Calif, USA
    • ,
  • Zenith Investigators,

      Affiliations

    • See Appendix.

Received 11 June 2003 ,Accepted 20 September 2003.

  • Image Result

    Effect of device oversizing (≤30% vs >30%) on AAA sac behavior at 12 months. AAA shrinkage (Shrink) was considered >5 mm reduction, Unchanged was −5 to +5 mm change, and Growth was >5 mm increase in s

    Effect of device oversizing (≤30% vs >30%) on AAA sac behavior at 12 months. AAA shrinkage (Shrink) was considered >5 mm reduction, Unchanged was −5 to +5 mm change, and Growth was >5 mm increase in size.

  • Image Result
    Effect of device oversizing (≤30% vs >30%) on AAA sac behavior at 24 months. AAA shrinkage (Shrink) was considered >5 mm reduction, Unchanged was −5 to +5 mm change, and Growth was >5 mm increase in s

    Effect of device oversizing (≤30% vs >30%) on AAA sac behavior at 24 months. AAA shrinkage (Shrink) was considered >5 mm reduction, Unchanged was −5 to +5 mm change, and Growth was >5 mm increase in size.

☆ All authors received research support from Cook to administer the phase II trial of the Zenith endograft. RKG and TAMC are consultants for Cook Inc.

PII: S0741-5214(03)01385-5

doi: 10.1016/j.jvs.2003.09.022

Journal of Vascular Surgery
Volume 39, Issue 1 , Pages 20-26 , January 2004

Article Tools

* Image Usage & Resolution